Richard Bernstein Advisors LLC Has $1.45 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX

Richard Bernstein Advisors LLC trimmed its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 52.4% in the third quarter, according to its most recent filing with the SEC. The fund owned 3,692 shares of the pharmaceutical company’s stock after selling 4,059 shares during the period. Richard Bernstein Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $1,446,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in VRTX. Vanguard Group Inc. raised its position in Vertex Pharmaceuticals by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 24,216,865 shares of the pharmaceutical company’s stock worth $9,484,293,000 after purchasing an additional 243,088 shares during the last quarter. Capital Research Global Investors boosted its stake in Vertex Pharmaceuticals by 2.8% during the third quarter. Capital Research Global Investors now owns 16,553,281 shares of the pharmaceutical company’s stock worth $6,482,978,000 after acquiring an additional 444,990 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Vertex Pharmaceuticals by 2.9% in the second quarter. Geode Capital Management LLC now owns 5,928,747 shares of the pharmaceutical company’s stock worth $2,627,135,000 after acquiring an additional 166,987 shares in the last quarter. Capital International Investors grew its stake in Vertex Pharmaceuticals by 77.9% in the third quarter. Capital International Investors now owns 4,689,059 shares of the pharmaceutical company’s stock valued at $1,836,550,000 after acquiring an additional 2,053,156 shares during the period. Finally, Alliancebernstein L.P. increased its holdings in shares of Vertex Pharmaceuticals by 10.7% during the second quarter. Alliancebernstein L.P. now owns 4,378,320 shares of the pharmaceutical company’s stock valued at $1,949,228,000 after acquiring an additional 424,808 shares in the last quarter. Institutional investors own 90.96% of the company’s stock.

Insider Activity

In related news, EVP Mark E. Bunnage sold 2,021 shares of the stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total value of $930,529.03. Following the sale, the executive vice president owned 12,914 shares in the company, valued at approximately $5,945,993.02. This trade represents a 13.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Amit Sachdev sold 58,613 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $468.83, for a total transaction of $27,479,532.79. Following the completion of the transaction, the executive vice president owned 58,934 shares in the company, valued at approximately $27,630,027.22. This trade represents a 49.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 91,156 shares of company stock worth $42,845,497. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Trading Up 8.3%

Shares of NASDAQ:VRTX opened at $499.17 on Wednesday. The stock has a market cap of $126.80 billion, a PE ratio of 32.56 and a beta of 0.31. The stock’s fifty day simple moving average is $468.41 and its two-hundred day simple moving average is $436.53. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.05 by ($0.02). Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The firm had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.18 billion. During the same quarter in the previous year, the company earned $3.98 EPS. The business’s revenue was up 9.5% compared to the same quarter last year. On average, sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Vertex Pharmaceuticals News Summary

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported positive Week‑36 interim results from the Phase 3 RAINIER trial for povetacicept — the study met its primary and all secondary endpoints, supporting the drug’s potential as a best‑in‑class treatment for IgA nephropathy. Vertex Announces Positive Week 36 Interim Analysis Results
• Positive Sentiment: News outlets note the trial win as a major validation — coverage emphasizes the result as a “key test” passed and calls the data “remarkable,” boosting confidence in Vertex’s kidney‑disease strategy. Vertex passes key test In quest to treat kidney diseases
• Positive Sentiment: Interim efficacy metrics cited in coverage (e.g., ~52% reduction in proteinuria) raise hopes for meaningful clinical benefit and potential for an accelerated FDA filing pathway, increasing the drug’s peak‑sales and valuation assumptions. VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug Study
• Positive Sentiment: Multiple brokerages responded quickly with higher price targets and fresh buy/outperform ratings (examples: Morgan Stanley, BofA, Oppenheimer, HC Wainwright, Citi, Jefferies, BMO and others), reflecting analysts modeling substantial upside from povetacicept. Benzinga — analyst price target coverage
• Neutral Sentiment: Vertex presented at the Leerink Global Healthcare Conference (transcript available), which may provide additional detail on timing, filing plans and commercial strategy but is less market‑moving than the trial headlines. Vertex Presents at Leerink Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Market commentary and aggregator pieces (Barron’s, Yahoo, Investopedia, TipRanks) are amplifying the newsflow — helpful for liquidity and momentum but reflecting the same core trial announcement rather than new independent data. Investopedia — trial results coverage

Analysts Set New Price Targets

A number of brokerages recently issued reports on VRTX. Citigroup increased their target price on Vertex Pharmaceuticals from $575.00 to $585.00 and gave the stock a “buy” rating in a report on Tuesday. Cantor Fitzgerald restated an “overweight” rating and set a $590.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, February 13th. Leerink Partners raised their price objective on shares of Vertex Pharmaceuticals from $456.00 to $525.00 and gave the company an “outperform” rating in a research note on Monday, December 29th. Weiss Ratings upgraded shares of Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, February 4th. Finally, Morgan Stanley boosted their target price on shares of Vertex Pharmaceuticals from $570.00 to $596.00 and gave the stock an “overweight” rating in a research report on Tuesday. Twenty-three analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $551.77.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.